New technology for screening for the presence of Barrett’s Oesophagus has been developed. The technology combines a device which allows for easy and accurate harvesting of the desired site with an improved diagnostic tool.
Social factors and an ageing population are causing the global incidence of Barrett’s Oesophagus (Barrett’s) to increase. It is estimated that 10% of patients with recurrent gastroesophageal reflux disease (GORD) will progress to Barrett’s. This equates to approximately 1-2% of the population. It has been estimated that there are approximately one million people in the USA with diagnosed pre-cancerous Barrett’s.
Current testing methods typically take 5 days and require to be conducted by experienced senior clinical staff plus dedicated pathology facilities; however results using this new technology can be obtained in twenty minutes via Enzyme-Linked Immunosorbent Assay (ELISA) techniques.
The sensitivity and specificity of the molecular markers have been demonstrated and offer an attractive alternative to the current biopsy technique; as well as being a potential tool for population screening or surveillance.
Summary of technology